ZA200602263B - Polymorphic forms of a known antihyperlipemic agent - Google Patents
Polymorphic forms of a known antihyperlipemic agent Download PDFInfo
- Publication number
- ZA200602263B ZA200602263B ZA200602263A ZA200602263A ZA200602263B ZA 200602263 B ZA200602263 B ZA 200602263B ZA 200602263 A ZA200602263 A ZA 200602263A ZA 200602263 A ZA200602263 A ZA 200602263A ZA 200602263 B ZA200602263 B ZA 200602263B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline form
- theta
- manufacture
- ray powder
- powder diffraction
- Prior art date
Links
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 20
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 5
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 4
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 4
- -1 compound tris(hydroxymethyl)methylammonium salt Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 3
- 239000011369 resultant mixture Substances 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 159000000007 calcium salts Chemical class 0.000 description 5
- 239000002002 slurry Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- VDXAJPMEBTVBFW-UHFFFAOYSA-N 5,5-dihydroxyhept-6-enoic acid Chemical group OC(=O)CCCC(O)(O)C=C VDXAJPMEBTVBFW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321827.8A GB0321827D0 (en) | 2003-09-18 | 2003-09-18 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200602263B true ZA200602263B (en) | 2007-11-28 |
Family
ID=29227290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200602263A ZA200602263B (en) | 2003-09-18 | 2007-03-17 | Polymorphic forms of a known antihyperlipemic agent |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070105882A1 (no) |
| EP (1) | EP1663990A1 (no) |
| JP (1) | JP2007505879A (no) |
| CN (1) | CN100439342C (no) |
| AU (1) | AU2004274239B2 (no) |
| BR (1) | BRPI0414499A (no) |
| CA (1) | CA2538756A1 (no) |
| GB (1) | GB0321827D0 (no) |
| IL (1) | IL174164A0 (no) |
| NO (1) | NO20061324L (no) |
| NZ (1) | NZ546007A (no) |
| WO (1) | WO2005028450A1 (no) |
| ZA (1) | ZA200602263B (no) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
| NL1015744C2 (nl) | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
| WO2003006439A1 (en) | 2001-07-13 | 2003-01-23 | Astrazeneca Uk Limited | Preparation of aminopyrimidine compounds |
| EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
| EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| DK1578731T3 (da) | 2002-12-16 | 2010-02-15 | Astrazeneca Uk Ltd | Fremgangsmåde til fremstilling af pyrimidinforbindelser |
| GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| GB0428328D0 (en) | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
| TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
| CA2749727A1 (en) * | 2009-01-15 | 2010-07-22 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of rosuvastatin salts |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
| CA3174516A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026698A (en) * | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US6278001B1 (en) * | 1995-11-28 | 2001-08-21 | L'oréal | Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping |
| GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| NL1015744C2 (nl) * | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
| US6777552B2 (en) * | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| JP2004536813A (ja) * | 2001-06-06 | 2004-12-09 | ブリストル−マイヤーズ スクイブ カンパニー | キラルジオールスルホンおよびジヒドロキシ酸ＨＭＧＣｏＡレダクタ−ゼ阻害剤 |
| GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| WO2005054207A1 (en) * | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
| US7241800B2 (en) * | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
-
2003
- 2003-09-18 GB GBGB0321827.8A patent/GB0321827D0/en not_active Ceased
-
2004
- 2004-09-17 CN CNB2004800268240A patent/CN100439342C/zh not_active Expired - Fee Related
- 2004-09-17 JP JP2006526703A patent/JP2007505879A/ja not_active Withdrawn
- 2004-09-17 NZ NZ546007A patent/NZ546007A/en unknown
- 2004-09-17 EP EP04768676A patent/EP1663990A1/en not_active Withdrawn
- 2004-09-17 BR BRPI0414499-6A patent/BRPI0414499A/pt not_active IP Right Cessation
- 2004-09-17 US US10/572,635 patent/US20070105882A1/en not_active Abandoned
- 2004-09-17 AU AU2004274239A patent/AU2004274239B2/en not_active Ceased
- 2004-09-17 CA CA002538756A patent/CA2538756A1/en not_active Abandoned
- 2004-09-17 WO PCT/GB2004/004133 patent/WO2005028450A1/en active Application Filing
-
2006
- 2006-03-07 IL IL174164A patent/IL174164A0/en unknown
- 2006-03-23 NO NO20061324A patent/NO20061324L/no not_active Application Discontinuation
-
2007
- 2007-03-17 ZA ZA200602263A patent/ZA200602263B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20061324L (no) | 2006-04-04 |
| EP1663990A1 (en) | 2006-06-07 |
| US20070105882A1 (en) | 2007-05-10 |
| JP2007505879A (ja) | 2007-03-15 |
| CN100439342C (zh) | 2008-12-03 |
| AU2004274239B2 (en) | 2008-12-04 |
| IL174164A0 (en) | 2006-08-01 |
| GB0321827D0 (en) | 2003-10-15 |
| NZ546007A (en) | 2008-11-28 |
| AU2004274239A1 (en) | 2005-03-31 |
| CA2538756A1 (en) | 2005-03-31 |
| CN1852899A (zh) | 2006-10-25 |
| WO2005028450A1 (en) | 2005-03-31 |
| BRPI0414499A (pt) | 2006-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200602263B (en) | Polymorphic forms of a known antihyperlipemic agent | |
| CA2356212C (en) | Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt | |
| EP1873148B1 (en) | Pharmaceutical compositions containing crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid | |
| EP1663989B1 (en) | CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT | |
| US9371291B2 (en) | Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof | |
| MXPA06003052A (en) | Polymorphic forms of a known antihyperlipemic agent | |
| KR20070017970A (ko) | 공지된 항고지혈증제의 다형성 형태 |